Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...
The Manila Times

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy i…

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...
Le Lézard

uMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical Trials

Motif ? one of the clinical trial technology market's fastest growing companies ? continues contributing to major innovations in how clinical trial patient data are collected, with Chief Scientific ...
The American Journal of Managed Care

Communication of Launch Prices by Drug Companies, 2022-2024

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

UK approves GSK's twice-yearly asthma drug

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...
STAT

Sobi bets big on next-gen gout drug

Milestone Pharmaceuticals won FDA approval for a new nasal-spray medicine to treat episodes of paroxysmal supraventricular ...
NC Biotech

History of Biotechnology in North Carolina

A catalyst for technology-based economic development in life sciences . In 1984, three of North Carolina’s largest ...